These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35831190)

  • 21. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.
    Yamamoto J; Ito T; Yamaguchi Y; Handa H
    Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting cereblon in hematologic malignancies.
    Fuchs O
    Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma.
    Charliński G; Vesole DH; Jurczyszyn A
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
    Burslem GM; Ottis P; Jaime-Figueroa S; Morgan A; Cromm PM; Toure M; Crews CM
    ChemMedChem; 2018 Aug; 13(15):1508-1512. PubMed ID: 29870139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Fink EC; McConkey M; Adams DN; Haldar SD; Kennedy JA; Guirguis AA; Udeshi ND; Mani DR; Chen M; Liddicoat B; Svinkina T; Nguyen AT; Carr SA; Ebert BL
    Blood; 2018 Oct; 132(14):1535-1544. PubMed ID: 30064974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.
    Shimizu N; Asatsuma-Okumura T; Yamamoto J; Yamaguchi Y; Handa H; Ito T
    Commun Biol; 2021 Nov; 4(1):1277. PubMed ID: 34764413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
    Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
    J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
    Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
    Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
    Zhou L; Xu G
    J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
    Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
    Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.
    Costacurta M; He J; Thompson PE; Shortt J
    J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.
    Sato T; Ito T; Handa H
    Front Cell Dev Biol; 2021; 9():629326. PubMed ID: 33777938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.
    Liu L; Sun R; Liu H; Ren C; Zhou Y; Qiu X; Kong Y; Jiang B; Yang X
    Eur J Med Chem; 2023 Feb; 247():115016. PubMed ID: 36577219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
    Petzold G; Fischer ES; Thomä NH
    Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.